Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

FORTIFI-HN01: Een fase 2/3-studie van Ficerafusp Alfa (BCA101) of Placebo in combinatie met Pembrolizumab in eerstelijns PD-L1-pos, R of M HNSCC (FORTIFI-HN01)

28 oktober 2026 bijgewerkt door: Bicara Therapeutics

Een multicenter, gerandomiseerde, dubbelblinde fase 2/3-studie van Ficerafusp Alfa (BCA101) of Placebo in combinatie met Pembrolizumab voor eerstelijnsbehandeling van PD-L1-positief, recidiverend of gemetastaseerd plaveiselcelcarcinoom van hoofd en nek

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).

This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Studie Overzicht

Gedetailleerde beschrijving

The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.

Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:

  • Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
  • Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
  • Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.

The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.

Studietype

Ingrijpend

Inschrijving (Geschat)

650

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Buenos Aires, Argentinië, C1190
      • Buenos Aires, Argentinië, C1425
      • Pilar, Argentinië, B1629ODT
        • Werving
        • Hospital Universitario Austral (Site # 2303)
        • Contact:
      • Rosario, Argentinië, CP2000
        • Werving
        • Sanatorio de la Mujer (Site # 2305)
        • Contact:
      • Santa Fe, Argentinië, S2002KDT
        • Werving
        • Hospital Provincial del Centenario (Site # 2302)
        • Contact:
    • New South Wales
      • Camperdown, New South Wales, Australië, 2050
        • Werving
        • Chris O'Brien Lifehouse (Site#0302)
        • Contact:
      • Kingswood, New South Wales, Australië, 2747
      • Waratah, New South Wales, Australië, 2298
        • Werving
        • Calvary Mater Newcastle (Site#0304)
        • Contact:
    • Queensland
      • Southport, Queensland, Australië, 4215
        • Werving
        • Gold Coast University Hospital (Site #0305)
        • Contact:
      • Tugun, Queensland, Australië, 4224
        • Werving
        • John Flynn Private Hospital (Site#0307)
        • Contact:
    • Victoria
      • Heidelberg, Victoria, Australië, 3084
      • North Melbourne, Victoria, Australië, 3051
        • Werving
        • Peter Macallum Cancer Centre (Site#0301)
        • Contact:
    • Western Australia
      • Murdoch, Western Australia, Australië, 6150
        • Werving
        • Fiona Stanley Hospital (Site#0308)
        • Contact:
      • Bruges, België, 8000
        • Werving
        • AZ St-Jan Brugge Oostende av (Campus Sint-Jan) (Site #1007)
        • Contact:
      • Mons, België, 7000
      • Namur, België, 5000
        • Werving
        • CHU UCL Namur, Site Ste. Elisabeth (Site #1002)
        • Contact:
      • Namur, België, 5530
        • Werving
        • CHU UCL Namur, Site Mont-Godinne (Site #1003)
        • Contact:
      • Sint-Niklaas, België, 9100
      • Wilrijk, België, 2610
      • Barretos, Brazilië, 14784-400
        • Werving
        • Hospital de Amor de Barretos - Fundação Pio XII (Site # 2413)
        • Contact:
      • Belém, Brazilië, 66063495
        • Werving
        • Centro de Tratamento Oncologico (Site # 2421)
        • Contact:
      • Curitiba, Brazilië, 80810-050
        • Werving
        • CIONC-Centro Integrado de Oncologia de Curitiba (Site # 2404)
        • Contact:
      • Fortaleza, Brazilië, 60430235
        • Werving
        • Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414)
        • Contact:
      • Ijuí, Brazilië, 98700-000
        • Werving
        • Oncosite - Centro de Pesquisa Clinica e Oncologia (Site # 2402)
        • Contact:
      • Jaú, Brazilië, 17210-120
        • Werving
        • Fundação Doutor Amaral Carvalho (Site # 2411)
        • Contact:
      • Natal, Brazilië, 59062-000
        • Werving
        • Liga Norte-Rio-Grandense Contra o Câncer (Site # 2422)
        • Contact:
      • Passo Fundo, Brazilië, 99010-260
        • Werving
        • Hospital de Clínicas de Passo Fundo (Site # 2419)
        • Contact:
      • Porto Alegre, Brazilië, 91350-200
        • Werving
        • Hospital Nossa Senhora da Conceicao (Site # 2403)
        • Contact:
      • Rio de Janeiro, Brazilië, 22250-905
        • Werving
        • Grupo Oncoclínicas (Site # 2412)
        • Contact:
      • Santa Cruz do Sul, Brazilië, 96835-100
      • Santa Lúcia, Brazilië, 30360680
        • Werving
        • Oncoclinicas do Brasil Serviços Médicos S.A - Oncocentro BH (Site # 2401)
        • Contact:
      • São Caetano do Sul, Brazilië, 09541-270
        • Werving
        • Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410)
        • Contact:
      • São José do Rio Preto, Brazilië, 15090-000
        • Werving
        • Centro Integrado de Pesquisa do Hospital de Base de São José do Rio Preto/FUNFAR (Site # 2406)
        • Contact:
      • São Paulo, Brazilië, 01246-000
        • Werving
        • Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417)
        • Contact:
      • São Paulo, Brazilië, 01509-900
        • Werving
        • A. C. Camargo Cancer Center (Site # 2409)
        • Contact:
      • São Paulo, Brazilië, 04014-002
        • Werving
        • IBCC Núcleo de Pesquisa e Ensino (Site # 2405)
        • Contact:
      • São Paulo, Brazilië, 04543
        • Werving
        • Oncoclínicas - SP (Site # 2416)
        • Contact:
      • São Paulo, Brazilië, 08270-120
        • Werving
        • Hospital Santa Marcelina (Site # 2418)
        • Contact:
    • Vitoria ES
      • Santa Cecília, Vitoria ES, Brazilië, 29043-260
        • Werving
        • AFECC Hospital Santa Rita de Cassia (Site # 2420)
        • Contact:
      • Toronto, Canada, M4N 3M5
        • Werving
        • Sunnybrook Health Sciences Centre (Site # 0204)
        • Contact:
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Werving
        • BC Cancer - Vancouver (Site #0202)
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada, H2X 0C1
        • Werving
        • Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (Site #0203)
        • Contact:
      • Aachen, Duitsland, 52074
        • Werving
        • Universitaetsklinikum Aachen AOeR (Site #0710)
        • Contact:
      • Berlin, Duitsland, 12200
        • Werving
        • Charite - Campus Benjamin Franklin (Site # 0701)
        • Contact:
      • Berlin, Duitsland, 12351
        • Werving
        • Vivantes Klinikum Neukoelln (Site # 0714)
        • Contact:
      • Braunschweig, Duitsland, 38114
        • Werving
        • Staedtisches Klinikum Braunschweig gGmbH (Site # 0709)
        • Contact:
      • Chemnitz, Duitsland, 09116
        • Werving
        • Klinikum Chemnitz gGmbH (Site # 0705)
        • Contact:
      • Dresden, Duitsland, 01067
        • Werving
        • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt (Site #0707)
        • Contact:
      • Dresden, Duitsland, 01307
        • Werving
        • Universitaetsklinikum Carl Gustav Carus TU Dresden (Site # 0711)
        • Contact:
      • Düsseldorf, Duitsland, 40225
        • Werving
        • Heinrich-Heine-Universitaet Duesseldorf (Site #0706)
        • Contact:
      • Essen, Duitsland, 45147
        • Werving
        • Universitaetsklinikum Essen (Site # 0716)
        • Contact:
      • Göttingen, Duitsland, 37075
        • Werving
        • Universitaetsmedizin Goettingen (Site # 0708)
        • Contact:
      • Hanover, Duitsland, 30625
        • Werving
        • Medizinische Hochschule Hannover (Site # 0718)
        • Contact:
      • Karlsruhe, Duitsland, 76137
        • Werving
        • Vincentius-Diakonissen-Kliniken gAG/St. Vincentius-Kliniken (Site #0717)
        • Contact:
      • München, Duitsland, 81675
        • Werving
        • Technische Universität München School of Medicine (Site # 0715)
        • Contact:
      • Stuttgart, Duitsland, 70174
        • Werving
        • Klinikum Stuttgart-Katharinenhospital (Site # 0703)
        • Contact:
      • Ulm, Duitsland, 89075
        • Werving
        • Universitaetsklinikum Ulm (Site # 0702)
        • Contact:
      • Amiens, Frankrijk, 80480
        • Werving
        • CHU Amiens - Hopital Sud (Site #0809)
        • Contact:
      • Bordeaux, Frankrijk, 33075
      • Lille, Frankrijk, 59000
        • Werving
        • Centre Oscar Lambret (Site # 0804)
        • Contact:
      • Lyon, Frankrijk, 69004
        • Werving
        • Centre Hospitalier de la Croix Rousse (Site #0810)
        • Contact:
      • Paris, Frankrijk, 75005
        • Werving
        • Institut Curie - site de Paris (Site # 0813)
        • Contact:
      • Rennes, Frankrijk, 35042
        • Werving
        • CRLCC Eugene Marquis (Site #0805)
        • Contact:
      • Saint-Grégoire, Frankrijk, 35760
        • Werving
        • Les Hopitaux Prives Rennais - Saint-Gregoire (Site #0807)
        • Contact:
      • Strasbourg, Frankrijk, 67200
        • Werving
        • Centre Regional Lutte Contre Le Cancer - PAUL STRAUSS (Site #0808)
        • Contact:
      • Toulouse, Frankrijk, 31059
      • Vandœuvre-lès-Nancy, Frankrijk, 54519
        • Werving
        • ICL - Alexis Vautrin (Site #0806)
        • Contact:
      • Villejuif, Frankrijk, 94805
        • Werving
        • Institut Gustave Roussy (Site #0801)
        • Contact:
      • Athens, Griekenland, 12461
        • Werving
        • U.G.H. ATTIKON - General Hospital of West Attica "H AGIA VARVARA" (Site # 1701)
        • Contact:
      • Larissa, Griekenland, 41110
        • Werving
        • University General Hospital of Larissa (Site # 1702)
        • Contact:
      • Cork, Ierland, T12 DC4A
        • Werving
        • Cork University Hospital - Consultants Private Clinic (Site # 0603)
        • Contact:
      • Dublin, Ierland, D08 NHY1
        • Werving
        • Trinity College Dublin (TCD) - St. James's Hospital (SJH) (Site #0602)
        • Contact:
      • Dublin, Ierland, D09 V2N0
      • Madurai, Indië, 625107
        • Werving
        • Meenakshi Mission Hospital & Research Centre (Site # 3003)
        • Contact:
      • Sūrat, Indië, 395004
      • Beersheba, Israël, 84101
        • Werving
        • Soroka Medical Center (Site # 1901)
        • Contact:
      • Jerusalem, Israël, 9112001
        • Werving
        • Hadassah Medical Center (Site # 1903)
        • Contact:
      • Petah Tikva, Israël, 49100
        • Werving
        • Rabin Medical Center (Site # 1904)
        • Contact:
      • Tel Aviv, Israël, 6423906
        • Werving
        • Sourasky Medical Center (Site # 1902)
        • Contact:
      • Bologna, Italië, 40138
        • Werving
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi (Site #0904)
        • Contact:
      • Cagliari, Italië, 09121
      • Florence, Italië, 50134
        • Werving
        • Azienda Ospedaliera Universitaria Careggi (Site #0911)
        • Contact:
      • Milan, Italië, 20132
        • Werving
        • Ospedale San Raffaele (Site #0907)
        • Contact:
      • Milan, Italië, 20133
        • Werving
        • Fondazione IRCCS Istituto Nazionale dei Tumori (Site #0901)
        • Contact:
      • Milan, Italië, 20142
        • Werving
        • ASST Santi Paolo e Carlo, Ospedale San Paolo Polo Universitario (Site #0905)
        • Contact:
      • Milan, Italië, 20162
        • Werving
        • Azienda Socio Sanitaria Territoriale Niguarda (Site # 0912)
        • Contact:
      • Naples, Italië, 80131
        • Werving
        • Istituto Nazionale Tumori Fondazione G. Pascale (Site #0915)
        • Contact:
      • Naples, Italië, 80131
        • Werving
        • UOC Oncoematologia AOU - University Luigi Vanvitelli (Site # 0916)
        • Contact:
      • Padova, Italië, 35128
        • Werving
        • IOV - Istituto Oncologico Veneto IRCCS (Site # 0910)
        • Contact:
      • Palermo, Italië, 90127
        • Werving
        • Policlinico P. Giaccone di Palermo (Site #0908)
        • Contact:
      • Pavia, Italië, 27100
        • Werving
        • Fondazione IRCCS Policlinico San Matteo (Site # 0903)
        • Contact:
      • Pisa, Italië, 56126
        • Werving
        • Azienda Ospedaliero Universitaria Pisana (Site # 0909)
        • Contact:
      • Rome, Italië, 00161
        • Werving
        • Azienda Ospedaliero-Universitaria Policlinico Umberto I (Site #0917)
        • Contact:
      • Rome, Italië, 00168
        • Werving
        • Fondazione Policlinico Universitario - Agostino Gemelli (Site #0918)
        • Contact:
      • Rome, Italië, 00186
        • Werving
        • Fatebenefratelli Isola Tiberina, Gemelli Isola (Site #0906)
        • Contact:
      • Rozzano, Italië, 20089
        • Werving
        • Humanitas Mirasole S.p.A (Site # 0919)
        • Contact:
      • Siena, Italië, 53100
        • Werving
        • A.O.U. Senese Policlinico Santa Maria alle Scotte (Site # 0902)
        • Contact:
      • Kōtoku, Japan, 135-8550
        • Werving
        • Cancer Institute Hospital of JFCR (Site # 3107)
        • Contact:
      • George Town, Maleisië, 11200
        • Werving
        • Mount Miriam Cancer Hospital (Site # 2802)
        • Contact:
      • Kuala Lumpur, Maleisië, 50586
        • Werving
        • Hospital Kuala Lumpur (Site # 2803)
        • Contact:
      • Kuala Lumpur, Maleisië, 59100
        • Werving
        • University Malaya Medical centre (Site # 2805)
        • Contact:
      • Kuching, Maleisië, 93200
        • Werving
        • Sarawak General Hospital (Site # 2801)
        • Contact:
      • Pulau Pinang, Maleisië, 10450
        • Werving
        • Hospital Pulau Pinang (Site # 2804)
        • Contact:
      • Christchurch, Nieuw-Zeeland, 8011
        • Werving
        • Christchurch Hospital NZ (Site #0401)
        • Contact:
      • Rotorua, Nieuw-Zeeland, 3010
      • Salzburg, Oostenrijk, 5020
        • Werving
        • Hematology and Medical Oncology, Paracelsus Medical University (Site #1602)
        • Contact:
      • Vienna, Oostenrijk, 1090
        • Werving
        • Medical University Vienna (Site #1601)
        • Contact:
      • Gdansk, Polen, 80-214
        • Werving
        • UNIWERSYTECKIE CENTRUM KLINICZNE (Site #1401)
        • Contact:
      • Gliwice, Polen, 44-102
        • Werving
        • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie (Site # 1405)
        • Contact:
      • Katowice, Polen, 40-519
        • Werving
        • Pratia Onkologia Katowice (Site #1403)
        • Contact:
      • Konin, Polen, 62-500
        • Werving
        • Przychodnia Lekarska Komed (Site #1407)
        • Contact:
      • Krakow, Polen, 31-826
        • Werving
        • Szpital Specjalistyczny im. L.Rydygiera w Krakowie (Site #1404)
        • Contact:
      • Siedlce, Polen, 08-110
        • Werving
        • Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o. (Site #1402)
        • Contact:
      • Warsaw, Polen, 02-781
        • Werving
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curiee - Panstwowy Instytut (Site #1406)
        • Contact:
      • Braga, Portugal, 4710-243
        • Werving
        • Centro Clínico Académico de Braga (Site #1506)
        • Contact:
      • Coimbra, Portugal
        • Werving
        • Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (Site #1503)
        • Contact:
      • Lisbon, Portugal, 1099-023
        • Werving
        • Instituto Português de Oncologia Lisboa (Site #1508)
        • Contact:
      • Portimão, Portugal, 8500-338
        • Werving
        • Centro Hospitalar Algarve (Site #1501)
        • Contact:
      • Porto, Portugal, 4200-072
        • Werving
        • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (Site #1505)
        • Contact:
      • Porto, Portugal, 4200-319
        • Werving
        • Centro Hospitalar Universitario de Sao Joao (Site #1507)
        • Contact:
      • Senhora da Hora, Portugal, 4464-509
        • Werving
        • Unidade Local de Saude de Matosinhos, E.P.E. - Hospital Pedro Hispano (Site #1502)
        • Contact:
      • Vila Nova de Gaia, Portugal, 4434-502
        • Werving
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E. (Site # 1504)
        • Contact:
      • Novena, Singapore, 308433
        • Werving
        • Tan Tock Seng Hospital (Site # 2902)
        • Contact:
      • Singapore, Singapore, 168583
        • Werving
        • National Cancer Centre Singapore (Site # 2901)
        • Contact:
      • Badalona, Spanje, 8916
        • Werving
        • ICO Badalona - Hospital Universitari Germans Trias i Pujol (Site # 1311)
        • Contact:
      • Barcelona, Spanje, 08035
        • Werving
        • Hospital Universitari Vall d'Hebron (Site #1301)
        • Contact:
      • Barcelona, Spanje, 08036
        • Werving
        • Hospital Clinic de Barcelona (Site #1305)
        • Contact:
      • Barcelona, Spanje, 08041
        • Werving
        • Hospital de la Santa Creu I Sant Pau Site #1304
        • Contact:
      • Barcelona, Spanje, 08908
        • Werving
        • Institut Catala d'Oncologia (Site # 1302)
        • Contact:
      • Madrid, Spanje, 28027
        • Werving
        • Clinica Universidad de Navarra- Madrid (Site #1310)
        • Contact:
      • Madrid, Spanje, 28041
        • Werving
        • Hospital Universitario 12 De Octubre (Site #1303)
        • Contact:
      • Pamplona, Spanje, 31008
        • Werving
        • Clinica Universidad de Navarra (Site #1306)
        • Contact:
      • Santander, Spanje, 39008
        • Werving
        • Hospital Universitario Marques de Valdecilla (HUMV) (Site #1309)
        • Contact:
      • Valencia, Spanje, 46010
        • Werving
        • Hospital Clinico Universitario de Valencia (Site #1307)
        • Contact:
      • Valencia, Spanje, 46014
        • Werving
        • Hospital General Universitario de Valencia (Site #1308)
        • Contact:
      • Changhua, Taiwan, 50006
        • Werving
        • Changhua Christian Medical Foundation Changhua Christian Hospital (Site # 2602)
        • Contact:
      • Kaohsiung City, Taiwan, 807
        • Werving
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (Site # 2601)
        • Contact:
      • Taichung, Taiwan, 40447
        • Werving
        • China Medical University Hospital (CMUH) (Site # 2603)
        • Contact:
      • Taipei, Taiwan, 10002
        • Werving
        • National Taiwan University Hospital (Site # 2604)
        • Contact:
      • Bangkok, Thailand, 10400
        • Werving
        • Phramongkutklao Hospital (Site # 2505)
        • Contact:
      • Bangkok, Thailand, 10400
        • Werving
        • Rajavithi Hospital (Site # 2504)
        • Contact:
      • Chiang Mai, Thailand, 50200
        • Werving
        • Maharaj Nakorn Chiang Mai Hospital (Site # 2506)
        • Contact:
      • Dusit, Thailand, 10300
      • Hat Yai, Thailand, 90110
        • Werving
        • Songklanagarind Hospital (Site # 2502)
        • Contact:
      • Hradec Králové, Tsjechië, 500 03
        • Werving
        • Fakultni Nemocnice Hradec Kralove (FNHK) (Site # 2101)
        • Contact:
      • Prague, Tsjechië, 15006
        • Werving
        • Fakultni nemocnice Motol a Homolka (Site #2102)
        • Contact:
      • Ankara, Turkije (Türkiye), 6100
        • Werving
        • Hacettepe University Medical Faculty (Site # 1201)
        • Contact:
      • Ankara, Turkije (Türkiye), 6520
        • Werving
        • Memorial Ankara Hospital (Site # 1202)
        • Contact:
      • Antalya, Turkije (Türkiye), 7020
        • Werving
        • Memorial Antalya Hastanesi (Site # 1204)
        • Contact:
      • Istanbul, Turkije (Türkiye), 34098
        • Werving
        • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203)
        • Contact:
      • Izmir, Turkije (Türkiye), 35330
        • Werving
        • Dokuz Eylul University Medical School (Site # 1206)
        • Contact:
      • Aberdeen, Verenigd Koninkrijk, AB25 2ZN
        • Werving
        • Aberdeen Royal Infirmary (Site #0504)
        • Contact:
      • Birmingham, Verenigd Koninkrijk, B15 2TH
        • Werving
        • University Hospitals Birmingham (Queen Elizabeth Hospital) (Site #0512)
        • Contact:
      • Cambridge, Verenigd Koninkrijk, CB2 0QQ
        • Werving
        • Cambridge University Hospitals (Site #0513)
        • Contact:
      • Glasgow, Verenigd Koninkrijk, G12 0YN
        • Werving
        • Beatson West of Scotland Cancer Centre (Site # 0510)
        • Contact:
      • Leeds, Verenigd Koninkrijk, LS9 7TF
        • Werving
        • St James University Hospital Leeds (Site #0511)
        • Contact:
      • Liverpool, Verenigd Koninkrijk, L7 8YA
        • Werving
        • Clatterbridge Cancer Center NHS Foundation (Site #0507)
        • Contact:
      • London, Verenigd Koninkrijk, SW3 6JJ
        • Werving
        • Royal Marsden Hospital - Chelsea (Site #0505)
        • Contact:
      • London, Verenigd Koninkrijk, WC1E 6AG
        • Werving
        • University College London Hospital (Site #0502)
        • Contact:
      • Manchester, Verenigd Koninkrijk, M20 4BX
        • Werving
        • The Christie Hospital (Site #0508)
        • Contact:
      • Middlesex, Verenigd Koninkrijk, HA6 2RN
        • Werving
        • Mount Vernon Cancer Centre (Site #0506)
        • Contact:
      • Newcastle upon Tyne, Verenigd Koninkrijk, NE7 7DN
        • Werving
        • Newcastle University (Site # 509)
        • Contact:
      • Nottingham, Verenigd Koninkrijk, NG5 1PB
        • Werving
        • Nottingham University Hospitals City Campus (Site #0503)
        • Contact:
      • Oxford, Verenigd Koninkrijk, OX3 7LE
      • Portsmouth, Verenigd Koninkrijk, PO6 3LY
        • Werving
        • Queen Alexandra Hospital (Site # 0514)
        • Contact:
      • Sutton, Verenigd Koninkrijk, SM2 5PT
        • Werving
        • Royal Marsden Hospital- London (Site # 0501)
        • Contact:
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • Werving
        • University of Alabama Hospital (Site # 0137)
        • Contact:
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85054
        • Werving
        • Mayo Clinic Hospital (Site #0147)
        • Contact:
    • California
      • La Jolla, California, Verenigde Staten, 92093
        • Werving
        • UC San Diego Moores Cancer Center (Site #0107)
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90095
        • Werving
        • UCLA Department of Medicine - Hematology/Oncology (Site #0106)
        • Contact:
      • Sacramento, California, Verenigde Staten, 95817
      • San Francisco, California, Verenigde Staten, 94143
        • Werving
        • University of California San Francisco (Site #0130)
        • Contact:
      • Stanford, California, Verenigde Staten, 94305
        • Werving
        • Stanford Cancer Institute (Site #0150)
        • Contact:
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80012
        • Werving
        • Rocky Mountain Cancer Centers, LLP (Site #0122)
        • Contact:
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • Rocky Mountain Regional VAMC (Site #0124)
        • Contact:
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
        • Contact:
    • Delaware
      • Newark, Delaware, Verenigde Staten, 19713
        • Werving
        • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
        • Contact:
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32224
        • Werving
        • Mayo Clinic Florida (Site #0148)
        • Contact:
      • Palm Bay, Florida, Verenigde Staten, 32901
        • Werving
        • Cancer Care Centers of Brevard (Site #0136)
        • Contact:
      • Tampa, Florida, Verenigde Staten, 33612
        • Werving
        • Moffit Cancer Center (Site #0105)
        • Contact:
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60064
        • Werving
        • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
        • Contact:
    • Iowa
      • Iowa City, Iowa, Verenigde Staten, 52242
        • Werving
        • University of Iowa Hospitals & Clinics (Site#0140)
        • Contact:
    • Kansas
      • Westwood, Kansas, Verenigde Staten, 66205
        • Werving
        • University of Kansas Medical Center Research Institute, Inc. (Site #0149)
        • Contact:
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40536
        • Werving
        • University of Kentucky, Markey Cancer Center (Site # 109)
        • Contact:
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Werving
        • Norton Cancer Institute (Site#0111)
        • Contact:
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Werving
        • The University of Louisville, James Graham Brown Cancer Center (Site#0115)
        • Contact:
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21201
        • Werving
        • University of Maryland Medical Group (Site #0112)
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital (Site #0131)
        • Contact:
      • Boston, Massachusetts, Verenigde Staten, 02136
        • Werving
        • Dana-Farber Cancer Institute (Site#0101)
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Werving
        • University of Michigan (Site # 161)
        • Contact:
    • Minnesota
      • Maplewood, Minnesota, Verenigde Staten, 55109
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic Cancer Center - Rochester (Site #0146)
        • Contact:
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School of Medicine (Site #0114)
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, Verenigde Staten, 07601
        • Werving
        • Hackensack Meridian Health (Site # 119)
        • Contact:
      • Newark, New Jersey, Verenigde Staten, 07103
        • Werving
        • Rutgers- Cancer Institute (Site #0145)
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10003
      • New York, New York, Verenigde Staten, 10021
        • Werving
        • Memorial Sloan Kettering Cancer Center (Site#0142)
        • Contact:
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27703
        • Werving
        • Duke University Health System (Site#0118)
        • Contact:
    • Ohio
      • Canton, Ohio, Verenigde Staten, 44708
      • Cincinnati, Ohio, Verenigde Staten, 45221
        • Werving
        • University of Cincinnati Cancer Institute (Site#0117)
        • Contact:
      • Cleveland, Ohio, Verenigde Staten, 44106
        • Werving
        • University Hospitals Seidman Cancer Center (Site #0151)
        • Contact:
      • Cleveland, Ohio, Verenigde Staten, 44195
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97213
        • Werving
        • Providence Portland Medical Center (Site #0113)
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15206
        • Werving
        • UPMC Hillman Cancer Center (Site #0103)
        • Contact:
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15240
        • Werving
        • VA Pittsburgh Healthcare System (Site #0123)
        • Contact:
    • Rhode Island
      • Providence, Rhode Island, Verenigde Staten, 02903
        • Werving
        • Lifespan Cancer Institute (Site #0132)
        • Contact:
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Werving
        • Medical University of South Carolina (MUSC) (Site#0104)
        • Contact:
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • SCRI-Oncology Partners (Site#0126)
        • Contact:
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Werving
        • Vanderbilt-Ingram Cancer Center (Site #0116)
        • Contact:
    • Texas
      • Houston, Texas, Verenigde Staten, 77005
        • Werving
        • MD Anderson Cancer Center (Site#0102)
        • Contact:
      • Waco, Texas, Verenigde Staten, 676712
        • Werving
        • SCRI- Texas Oncology- Central South (Site #0152)
        • Contact:
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22904
        • Werving
        • University of Virginia (Site#0134)
        • Contact:
      • Richmond, Virginia, Verenigde Staten, 23219
        • Werving
        • Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129)
        • Contact:
      • Richmond, Virginia, Verenigde Staten, 23249
        • Werving
        • Richmond Department of Veterans Affairs (Site #0138)
        • Contact:
    • Washington
      • Edmonds, Washington, Verenigde Staten, 98026
        • Werving
        • Swedish Cancer Institute - North Campus Edmonds (Site # 0160)
        • Contact:
      • Seattle, Washington, Verenigde Staten, 98104
        • Werving
        • Swedish Cancer Institute (Site # 0159)
        • Contact:
      • Seattle, Washington, Verenigde Staten, 98109
        • Werving
        • University of Washington - Seattle Cancer Care Alliance (Site #0125)
        • Contact:
      • Vancouver, Washington, Verenigde Staten, 98684
        • Werving
        • Northwest Cancer Specialists, PC (Site#0120)
        • Contact:
    • Wisconsin
      • Madison, Wisconsin, Verenigde Staten, 53705
        • Werving
        • William S. Middleton Memorial Veteran's Hospital (Site #0141)
        • Contact:
      • Madison, Wisconsin, Verenigde Staten, 53792
        • Werving
        • University of Wisconsin Hospital and Clinics (Site #0157)
        • Contact:
      • Milwaukee, Wisconsin, Verenigde Staten, 53233
        • Werving
        • Advocate Aurora Research Institute (Site # 0153)
        • Contact:
      • Busan, Zuid -Korea, 49267
        • Werving
        • Kosin University Gospel Hospital (Site # 2707)
        • Contact:
      • Goyang-si, Zuid -Korea, 10408
        • Werving
        • National Cancer Center (Site # 2704)
        • Contact:
      • Hwasun, Zuid -Korea, 58128
        • Werving
        • Chonnam National University Hwasun Hospital (Site # 2705)
        • Contact:
      • Seongnam, Zuid -Korea, 13620
        • Werving
        • Seoul National University Bundang Hospital (Site # 2706)
        • Contact:
      • Seoul, Zuid -Korea, 3080
        • Werving
        • Seoul National University Hospital (Site # 2701)
        • Contact:
      • Seoul, Zuid -Korea, 3722
        • Werving
        • SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)
        • Contact:
      • Seoul, Zuid -Korea, 6351
        • Werving
        • Samsung Medical Center (Site # 2703)
        • Contact:
      • Fribourg, Zwitserland, 1752
        • Werving
        • HFR Fribourg Kantonsspital Fribourg (Site # 1803)
        • Contact:
      • Geneva, Zwitserland, 1205
        • Werving
        • Hopitaux Universitaires de Geneve (Site # 1802)
        • Contact:
      • Lausanne, Zwitserland, 1011
        • Werving
        • Centre Hospitalier Universitaire Vaudois (CHUV) (Site # 1801)
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age ≥18 years on the day the Informed Consent Form is signed.
  • Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
  • No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
  • Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
  • PD-L1 CPS ≥1.
  • Measurable disease based on RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function, as defined in the protocol.

Exclusion Criteria:

  • Disease suitable for local therapy administered with curative intent.
  • Prior treatment with anti-TGFβ therapy.
  • Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
  • Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
  • Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
  • Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
  • Life expectancy less than 3 months.
  • Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
  • Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
  • Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
  • Active autoimmune disease requiring systemic treatment in the past 2 years.
  • Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
  • Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
  • Known history of human immunodeficiency virus (HIV).
  • Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
  • Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
  • Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
  • Use of a live or live attenuated vaccine within 4 weeks prior to Screening.

Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Phase 2 Arm A

ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)

Investigational

Immunotherapy agent used in combination with investigational agent

Experimenteel: Phase 2 Arm B

ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Placebo-vergelijker: Phase 2 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Experimenteel: Phase 3 OBD Arm

ficerafusp alfa OBD + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Placebo-vergelijker: Phase 3 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Tijdsspanne: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)
Tijdsspanne: Approximately 1 year.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 1 year.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 2 years.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 2 years.
Phase 3 - Overall Survival (OS)
Tijdsspanne: Approximately 3 years.

OS: Defined as the time from the randomization to death due to any cause.

Approximately 3 years.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 1 year.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR.

Approximately 1 year.
Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Tijdsspanne: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.

PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first.

Approximately 3 years.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.

ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).

Approximately 3 years.
Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.

Clinical Benefit Rate: For subject who demonstrated CR + PR + SD>6 months per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.
Tijdsspanne: Approximately 3 years.

ORR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.
Tijdsspanne: Approximately 3 years.

DOR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.
Tijdsspanne: Approximately 3 years.

PFS, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)
Tijdsspanne: Approximately 3 years.

To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function.

Approximately 3 years.
Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.
Tijdsspanne: Approximately 3 years.

To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden.

Approximately 3 years.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

28 januari 2025

Primaire voltooiing (Geschat)

1 april 2028

Studie voltooiing (Geschat)

1 juli 2029

Studieregistratiedata

Eerst ingediend

10 januari 2025

Eerst ingediend dat voldeed aan de QC-criteria

17 januari 2025

Eerst geplaatst (Werkelijk)

23 januari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

28 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren